Back to Results

Abcellera Biologics Inc (ABCL)

AbCellera Biologics Inc. is a healthcare company focused on discovering and developing antibody-based medicines for diseases with unmet medical needs in the United States. Its pipeline includes ABCL635, a non-hormonal medicine in Phase 2 testing for moderate to severe vasomotor symptoms, and ABCL575, a fully human, half-life extended monoclonal antibody in Phase 1 development for T-cell-mediated autoimmune conditions such as atopic dermatitis. The company has collaboration and license agreements with Eli Lilly and Company and AbbVie Inc., and it also has partnership arrangements involving Viking Global Investors & ArrowMark Partners and Biogen Inc. Founded in 2012, AbCellera is headquartered in Vancouver, Canada.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Next Earnings Date Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-ABCL
$7.76
-38.6% Downside
Overvalued
$17.13
35.4% Upside
Undervalued
Fair
0.0%
November 10, 2026
4.6x
62.0x
4.099 B
3.606 B
3.2%
68.2%
7.3
72.7%
Valuation • Fair Value

Abcellera Biologics Inc (NASDAQ-ABCL) Fair Value by Valuation Model

Review the available estimates for Abcellera Biologics Inc (NASDAQ-ABCL), including DCF Fair Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$7.76

Estimated downside of 38.6% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

DCF Fair Value

$5.26

Discounted cash flow valuation reference.

Comps Fair Value

$8.18

Comparable-company valuation reference.

Analyst Price Target

$17.13

Analysts imply upside of 35.4%.

How to read these valuation models

Use the 5 available valuation references for Abcellera Biologics Inc (NASDAQ-ABCL) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Abcellera Biologics Inc (NASDAQ-ABCL)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

66.17 M

Current operating scale indicator.

Revenue Forecast

24.163 M

Forward revenue estimate.

EBITDA

-200 M

Current operating profitability reference.

EBITDA Forecast

-201.1 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Abcellera Biologics Inc (NASDAQ-ABCL) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Abcellera Biologics Inc (NASDAQ-ABCL)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

4

Mid-range quality score.

Beneish M-Score

-1.91

Intermediate zone that deserves monitoring.

Altman Z-Score

7.3

Relatively strong balance-sheet zone.

FCF / Net Income

72.7%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Abcellera Biologics Inc (NASDAQ-ABCL). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Abcellera Biologics Inc (NASDAQ-ABCL)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 10, 2026

Days to Earnings

49

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Abcellera Biologics Inc (NASDAQ-ABCL), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Abcellera Biologics Inc (NASDAQ-ABCL) Stock Forecast & Technical Outlook

Review Abcellera Biologics Inc (NASDAQ-ABCL) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Abcellera Biologics Inc (NASDAQ-ABCL) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Neutral

The 1-hour technical read for Abcellera Biologics Inc (NASDAQ-ABCL) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Buy

The daily technical read for Abcellera Biologics Inc (NASDAQ-ABCL) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Buy

The weekly technical read for Abcellera Biologics Inc (NASDAQ-ABCL) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Buy

The monthly technical read for Abcellera Biologics Inc (NASDAQ-ABCL) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Abcellera Biologics Inc (NASDAQ-ABCL)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Abcellera Biologics Inc (NASDAQ-ABCL) has a Strong Buy consensus, with 8 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 8
Hold 0
Sell 0
FAQ • Fast Investor Answers

Abcellera Biologics Inc (NASDAQ-ABCL) Stock FAQ

Data-supported answers about Abcellera Biologics Inc (NASDAQ-ABCL), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$7.76
Estimated downside 38.6%
Valuation Rating
Overvalued
Estimated downside of 38.6%
Analyst Target
$17.13
Implied upside 35.4%
Financial Health
Fair
Current financial-health read

The current fair value estimate for Abcellera Biologics Inc (NASDAQ-ABCL) is $7.76. This implies an estimated downside of 38.6% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 38.6% versus the current market price.

The available analyst price target for Abcellera Biologics Inc (NASDAQ-ABCL) is $17.13. The analyst target implies estimated upside of 35.4%.

The current financial health read for Abcellera Biologics Inc (NASDAQ-ABCL) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Abcellera Biologics Inc (NASDAQ-ABCL) is November 10, 2026.

The latest available data indicates no current dividend yield for Abcellera Biologics Inc (NASDAQ-ABCL).

The current market capitalization listed for Abcellera Biologics Inc is 4.099 B.

The current enterprise value listed for Abcellera Biologics Inc is 3.606 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Abcellera Biologics Inc is NASDAQ-ABCL, and the stock is listed on NASDAQ.

Abcellera Biologics Inc (NASDAQ-ABCL) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Abcellera Biologics Inc is 3.2%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Abcellera Biologics Inc is 68.2%. Free float helps investors understand how much of the share base is available for public trading.

Similar Life Sciences Tools & Services Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

TMO NYSE Thermo Fisher Scientific Inc Fair Value Fair Market Cap 243.5 B
DHR NYSE Danaher Corporation Fair Value Fair Market Cap 155.4 B
A NYSE Agilent Technologies Inc Fair Value Fair Market Cap 47.155 B
IQV NYSE IQVIA Holdings Inc Fair Value Fair Market Cap 44.457 B
WAT NYSE Waters Corporation Fair Value Overvalued Market Cap 41.828 B
ILMN NASDAQ Illumina Inc Fair Value Overvalued Market Cap 37.366 B
MTD NYSE Mettler-Toledo International Inc Fair Value Fair Market Cap 29.87 B
WST NYSE West Pharmaceutical Services Inc Fair Value Fair Market Cap 26.116 B
MEDP NASDAQ Medpace Holdings Inc Fair Value Fair Market Cap 17.59 B
RVTY NYSE Revvity Inc Fair Value Fair Market Cap 15.991 B
TEM NASDAQ Tempus AI Inc Fair Value Overvalued Market Cap 13.928 B
CRL NYSE Charles River Laboratories Fair Value Fair Market Cap 13.611 B
ICLR NASDAQ ICON PLC Fair Value Fair Market Cap 12.894 B
TECH NASDAQ Bio-Techne Corp Fair Value Fair Market Cap 11.377 B
RGEN NASDAQ Repligen Corporation Fair Value Overvalued Market Cap 10.539 B
TXG NASDAQ 10X Genomics Inc Fair Value Overvalued Market Cap 10.514 B
AVTR NYSE Avantor Inc Fair Value Fair Market Cap 10.105 B
BIOB NYSE Bio-Rad Laboratories B Fair Value Fair Market Cap 10.076 B
BIO NYSE Bio-Rad Laboratories Inc Fair Value Fair Market Cap 10.076 B
BRKR NASDAQ Bruker Corporation Fair Value Fair Market Cap 9.326 B